Diabetes: Page
-
Courtesy of Eli Lilly
Lilly agrees to lower insulin prices by 70%
The pharma company, along with its diabetes drug rivals Novo Nordisk and Sanofi, has long been under pressure over the high cost of insulin — scrutiny that has recently ramped up in the U.S.
By Jonathan Gardner • March 1, 2023 -
Courtesy of Medtronic
Medtronic links MiniMed 780G automated insulin delivery to sustained glucose control benefits
The data indicates patients should receive automated insulin delivery earlier, rather than starting treatment with multiple daily injections, Medtronic said.
By Nick Paul Taylor • Feb. 27, 2023 -
Explore the Trendline➔
Courtesy of Johnson & Johnson
TrendlineNew medical devices are reshaping the medtech industry
From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.
By MedTech Dive staff -
Courtesy of Insulet Corp.
Insulet exceeds sales forecast amid signs Omnipod 5 is winning share in diabetes pump market
The pump will be a “share taker for some time to come,” as patients switch from rival devices, said Insulet’s CFO.
By Nick Paul Taylor • Feb. 24, 2023 -
Courtesy of Tandem Diabetes
Tandem sees growth in new product launches after $95M loss on decline in pump placements
Craig Hallum analysts said 2022 was a “tough year” for Tandem but noted the company’s 2023 forecast should “properly” set expectations.
By Elise Reuter • Feb. 23, 2023 -
Justin Sullivan via Getty Images
Apple makes strides in watch-based blood glucose tracking, Bloomberg reports
The company has been working on needle-free blood glucose tracking technology for 12 years, but has yet to show any meaningful clinical data, a J.P. Morgan analyst wrote.
By Elise Reuter • Feb. 22, 2023 -
Permission granted by Embecta
Embecta raises 2023 earnings forecast after better-than-expected start
Almost a year after the company spun off from Becton Dickinson, CEO Dev Kurdikar said Embecta’s quarterly results “exceeded our initial expectations” in a challenging market.
By Elise Reuter • Feb. 15, 2023 -
Courtesy of Insulet Corp.
Insulet pays Bigfoot Biomedical $25M for pump-based automated insulin delivery technology
Insulet framed the Bigfoot deal as a way to double its IP portfolio and strengthen its position in the insulin pump market.
By Nick Paul Taylor • Feb. 14, 2023 -
Courtesy of Dexcom
Dexcom secures Medicare coverage for G7 CGM with device set to launch this week
The decision by the CMS will include coverage for people with Type 1 and Type 2 diabetes who are on intensive insulin therapy.
By Elise Reuter • Feb. 13, 2023 -
Courtesy of Dexcom, Nick Jonas Super Bowl kit
Dexcom reports another record year of new customers amid continued demand for G6 device
The diabetes tech firm aims to keep boosting awareness of its CGMs with another Super Bowl commercial.
By Elise Reuter • Feb. 9, 2023 -
Permission granted by Abbott Laboratories
Abbott device approval sets up battle with Medtronic, Nevro for diabetic peripheral neuropathy treatment
Three firms are bringing their devices to a $3 billion to $5 billion market, aiming to relieve a painful side effect of diabetes.
By Elise Reuter • Feb. 6, 2023 -
Getty Images
Medtech earnings highlights: Easing of macro pressures, accelerated growth in 2023
Still, the latest round of quarterly results show that hospital staffing and supply chain remain a challenge.
By Nick Paul Taylor • Feb. 6, 2023 -
Permission granted by Tandem Diabetes Care
Q&AFriday Q&A: Tandem’s chief strategy officer talks tubeless pumps, Type 2 plans
Elizabeth Gasser also discusses the company’s recent acquisition of AMF Medical as well as how it factors environmental impact into device design.
By Elise Reuter • Jan. 27, 2023 -
Courtesy of Abbott Laboratories
Abbott sees ‘signs of stability’ for 2023 as hospital staffing, supply chain improves
While the company continues to grapple with supply shortages and procedure restrictions, it sold more COVID-19 tests than expected in the fourth quarter.
By Elise Reuter • Jan. 25, 2023 -
Courtesy of Insulet Corp.
Insulet reports personal-data leak of 29,000 insulin pump customers
In a recall communication to users, Insulet shared information with its website performance and marketing partners through cookies and other trackers embedded in its website.
By Nick Paul Taylor • Jan. 24, 2023 -
Getty Images
Deep Dive // Medtech trends in 2023Diabetes outlook: What Dexcom, Medtronic and other leaders are watching in 2023
From new product launches to regulatory changes that could expand CGM coverage, company executives and analysts share their predictions.
By Elise Reuter • Jan. 20, 2023 -
Permission granted by Dexcom
Q&ADexcom CEO discusses 2023 plans, expanding to more patients with Type 2 diabetes
MedTech Dive caught up with Kevin Sayer for a conversation about forthcoming product launches and long-term plans to expand CGMs to a broader group of patients.
By Elise Reuter • Updated Jan. 20, 2023 -
Permission granted by Abbott Laboratories
How Abbott plans to make its Freestyle Libre a $10B product
CEO Robert Ford discussed plans to grow the market for Abbott’s continuous glucose monitors, and its broader diabetes strategy.
By Elise Reuter • Jan. 10, 2023 -
Courtesy of Beta Bionics
Beta Bionics hires Harvard diabetes expert as CMO ahead of artificial pancreas launch
Steven Russell has joined the company as chief medical officer, completing a new leadership team that began taking shape with the appointment of Sean Saint as CEO last year.
By Nick Paul Taylor • Jan. 10, 2023 -
Courtesy of Dexcom
Dexcom forecasts 2023 revenue to rise as much as 20% on G7 launch
Sales are expected to reach $3.35 billion to $3.49 billion for the full year.
By Elise Reuter • Jan. 9, 2023 -
Courtesy of Medtronic
‘Mea culpa’: What Goldman Sachs analysts got wrong about Medtronic in 2022
Medtronic has struggled to deliver on key projects in recent years, leading to a decline in its stock performance.
By Nick Paul Taylor • Jan. 4, 2023 -
Getty Images
As diabetes technology advances, blood glucose control declines: study
Mexican-American and non-Hispanic Black adults saw the greatest drop as the proportion of patients with glycemic control fell from 29.2% between 1988 and 1994 to 27.5% between 2013 and 2020.
By Nick Paul Taylor • Dec. 21, 2022 -
Getty Images
Novo Nordisk expands Amalgam Rx insulin app pact, plots integration with other devices
Supported by Novo Nordisk, Amalgam Rx will incorporate and integrate with connected insulin delivery devices, continuous glucose monitors and electronic health records.
By Nick Paul Taylor • Dec. 20, 2022 -
Courtesy of Dexcom
Dexcom’s Jake Leach discusses preparations for G7 launch next year
The diabetes tech company is in conversations with payers and is opening a new manufacturing plant ahead of the planned launch of its newest CGM, the COO said.
By Elise Reuter • Dec. 15, 2022 -
Courtesy of Tandem Diabetes
Tandem agrees to buy AMF, challenging Insulet for insulin pump patch market
The deal will give Tandem control of Sigi, a reusable, rechargeable patch pump that is designed to be smaller and lighter than existing devices.
By Nick Paul Taylor • Dec. 14, 2022 -
Courtesy of Ypsomed
Ypsomed seeks new partner for US insulin pump launch as Lilly quits deal
The companies planned to launch a customized version of the YpsoPump that used pre-filled insulin cartridges for Lilly’s rapid-acting insulins.
By Nick Paul Taylor • Dec. 12, 2022
Previous
